A Safety & Effectiveness Study of Intravenous Anidulafungin With AmBisome® for Treatment of Invasive Aspergillosis (IA).
Status:
Completed
Trial end date:
2003-02-01
Target enrollment:
Participant gender:
Summary
The combination of Anidulafungin plus AmBisome® may offer an improved outcome for patients
treated for Invasive Aspergillosis (IA). The purpose of this study is to determine the safety
and the clinical and microbiological effectiveness of anidulafungin plus AmBisome® in treated
patients located in the United States, Europe, and South Africa.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Pfizer
Collaborator:
Vicuron Pharmaceuticals
Treatments:
Anidulafungin Echinocandins Liposomal amphotericin B